BMSC-derived leptin and IGFBP2 promote erlotinib resistance in lung adenocarcinoma cells through IGF-1R activation in hypoxic environment

Referance

• Emlet DR, Brown KA, Kociban DL, Pollice AA, Smith CA, Ong BB, Shackney SE. 2007. Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. Mol Cancer Ther. 6(10):2664–2674. doi:10.1158/1535-7163.MCT-07-0079.
   PubMed Web of Science ®Google Scholar
• Lee VH, Tin VP, Choy TS, Lam KO, Choi CW, Chung LP, Tsang JW, Ho PP, Leung DK, Ma ES, et al. 2013. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer. J Thorac Oncol. 8(9):1148–1155. doi:10.1097/JTO.0b013e31829f684a.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al. 2005. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 353(2):123–132. doi:10.1056/NEJMoa050753.
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, Gonzalez EE. 2012. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 13(3):300–308. doi:10.1016/S1470-2045(11)70385-0.
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, Esteban E, Molinier O, Brugger W, Melezinek I, et al. 2010. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 11(6):521–529. doi:10.1016/S1470-2045(10)70112-1.
   PubMed Web of Science ®Google Scholar
• Karam I, Melosky B. 2012. Response to second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer: make no assumptions. Curr Oncol. 19(1):42–46. doi:10.3747/co.19.949.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al. 2009. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361(10):947–957. doi:10.1056/NEJMoa0810699.
   PubMed Web of Science ®Google Scholar
• Lee JK, Shin JY, Kim S, Lee S, Park C, Kim JY, Koh Y, Keam B, Min HS, Kim TM, et al. 2013. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. Ann Oncol. 24(8):2080–2087. doi:10.1093/annonc/mdt127.
   PubMed Web of Science ®Google Scholar
• Remon J, Moran T, Majem M, Reguart N, Dalmau E, Marquez-Medina D, Lianes P. 2014. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins. Cancer Treat Rev. 40(1):93–101. doi:10.1016/j.ctrv.2013.06.002.
   PubMed Web of Science ®Google Scholar
• Filosto S, Baston DS, Chung S, Becker CR, Goldkorn T. 2013. Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells. Mol Cancer Ther. 12(8):1579–1590. doi:10.1158/1535-7163.MCT-12-1029.
   PubMed Web of Science ®Google Scholar
• Salem A, Asselin MC, Reymen B, Jackson A, Lambin P, West CML, O’Connor JPB, Faivre-Finn C. 2018. Targeting hypoxia to improve non-small cell lung cancer outcome. J Natl Cancer Inst. 2018;110(1):14–30.
   PubMedGoogle Scholar
• Murakami A, Takahashi F, Nurwidya F, Kobayashi I, Minakata K, Hashimoto M, Nara T, Kato M, Tajima K, Shimada N, et al. 2014. Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor. PLoS One. 9(1):e86459. doi:10.1371/journal.pone.0086459.
   PubMed Web of Science ®Google Scholar
• Klopp AH, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, Meyn RE, Cox JD, Andreeff M, Marini FC. 2007. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res. 67(24):11687–11695. doi:10.1158/0008-5472.CAN-07-1406.
   PubMed Web of Science ®Google Scholar
• Hsu SH, Chen CT, Wei YH. 2013. Inhibitory effects of hypoxia on metabolic switch and osteogenic differentiation of human mesenchymal stem cells. Stem Cells. 31(12):2779–2788. doi:10.1002/stem.1441.
   PubMed Web of Science ®Google Scholar
• Jaramillo ML, Banville M, Collins C, Paul-Roc B, Bourget L, O’Connor-McCourt M. 2008. Differential sensitivity of A549 non-small lung carcinoma cell responses to epidermal growth factor receptor pathway inhibitors. Cancer Biol Ther. 7(4):557–568. doi:10.4161/cbt.7.4.5533.
   PubMed Web of Science ®Google Scholar
• Chow DC, Wenning LA, Miller WM, Papoutsakis ET. 2001. Modeling pO(2) distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models. Biophys J. 81(2):685–696. doi:10.1016/S0006-3495(01)75733-5.
   PubMed Web of Science ®Google Scholar
• Hockel M, Vaupel P. 2001. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 93(4):266–276. doi:10.1093/jnci/93.4.266.
   PubMedGoogle Scholar
• Jiang C, Sun J, Dai Y, Cao P, Zhang L, Peng S, Zhou Y, Li G, Tang J, Xiang J. 2015. HIF-1A and C/EBPs transcriptionally regulate adipogenic differentiation of bone marrow-derived MSCs in hypoxia. Stem Cell Res Ther. 6:21.
   PubMed Web of Science ®Google Scholar
• Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, et al. 2005. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A. 102(21):7665–7670. doi:10.1073/pnas.0502860102.
   PubMed Web of Science ®Google Scholar
• Niederst MJ, Engelman JA. 2013. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci Signal. 6(294):re6. doi:10.1126/scisignal.2004652.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Nosaki K, Otsubo K, Azuma K, Sakata S, Ouchi H, Morinaga R, Wataya H, Fujii A, Nakagaki N, et al. 2017. Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naive patients with non-small cell lung cancer harboring EGFR mutations. Oncotarget. 8(40):68123–68130. doi:10.18632/oncotarget.19243.
   PubMedGoogle Scholar
• Alexander PB, Wang XF. 2015. Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies. Front Med. 9(2):134–138. doi:10.1007/s11684-015-0396-9.
   PubMed Web of Science ®Google Scholar
• Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, et al. 2010. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 17(1):77–88. doi:10.1016/j.ccr.2009.11.022.
   PubMed Web of Science ®Google Scholar
• Calvayrac O, Mazieres J, Figarol S, Marty-Detraves C, Raymond-Letron I, Bousquet E, Farella M, Clermont-Taranchon E, Milia J, Rouquette I, et al. 2017. The RAS-related GTPase RHOB confers resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer via an AKT-dependent mechanism. EMBO Mol Med. 9(2):238–250. doi:10.15252/emmm.201606646.
   PubMed Web of Science ®Google Scholar
• Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, et al. 2008. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest. 118(7):2609–2619. doi:10.1172/JCI34588.
   PubMed Web of Science ®Google Scholar
• Basen-Engquist K, Chang M. 2011. Obesity and cancer risk: recent review and evidence. Curr Oncol Rep. 13(1):71–76. doi:10.1007/s11912-010-0139-7.
   PubMed Web of Science ®Google Scholar
• Lashinger LM, Rossi EL, Hursting SD. 2014. Obesity and resistance to cancer chemotherapy: interacting roles of inflammation and metabolic dysregulation. Clin Pharmacol Ther. 96(4):458–463. doi:10.1038/clpt.2014.136.
   PubMed Web of Science ®Google Scholar
• Roberts DL, Dive C, Renehan AG. 2010. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med. 61::301–316. doi:10.1146/annurev.med.080708.082713.
   PubMed Web of Science ®Google Scholar
• Laursen T, Flyvbjerg A, Jorgensen JO, Baxter RC, Christiansen JS. 2000. Stimulation of the 150-kilodalton insulin-like growth factor-binding protein-3 ternary complex by continuous and pulsatile patterns of growth hormone (GH) administration in GH-deficient patients. J Clin Endocrinol Metab. 85(11):4310–4314. doi:10.1210/jcem.85.11.6957.
   PubMed Web of Science ®Google Scholar
• Ferry RJ Jr., Cerri RW, Cohen P. 1999. Insulin-like growth factor binding proteins: new proteins, new functions. Horm Res. 51(2):53–67. doi:10.1159/000023315.
   PubMedGoogle Scholar
• Shen X, Xi G, Maile LA, Wai C, Rosen CJ, Clemmons DR. 2012. Insulin-like growth factor (IGF) binding protein 2 functions coordinately with receptor protein tyrosine phosphatase beta and the IGF-I receptor to regulate IGF-I-stimulated signaling. Mol Cell Biol. 32(20):4116–4130. doi:10.1128/MCB.01011-12.
   PubMed Web of Science ®Google Scholar
• Kiepe D, Ulinski T, Powell DR, Durham SK, Mehls O, Tonshoff B. 2002. Differential effects of insulin-like growth factor binding proteins-1, −2, −3, and −6 on cultured growth plate chondrocytes. Kidney Int. 62(5):1591–1600. doi:10.1046/j.1523-1755.2002.00603.x.
   PubMed Web of Science ®Google Scholar
• Frommer KW, Reichenmiller K, Schutt BS, Hoeflich A, Ranke MB, Dodt G, Elmlinger MW. 2006. IGF-independent effects of IGFBP-2 on the human breast cancer cell line Hs578T. J Mol Endocrinol. 37(1):13–23. doi:10.1677/jme.1.01955.
   PubMed Web of Science ®Google Scholar
• McCaffery I, Tudor Y, Deng H, Tang R, Suzuki S, Badola S, Kindler HL, Fuchs CS, Loh E, Patterson SD, et al. 2013. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor. Clin Cancer Res. 19(15):4282–4289. doi:10.1158/1078-0432.CCR-12-1840.
   PubMed Web of Science ®Google Scholar